Overall Tolerability of Integrase Inhibitors in Clinical Practice: Results from a Multicenter Italian Cohort-Reference-Cited by-同舟云学术

Overall Tolerability of Integrase Inhibitors in Clinical Practice: Results from a Multicenter Italian Cohort

Published:2021-01-01 Issue:1 Volume:37 Page:4-10
ISSN:0889-2229
Container-title:AIDS Research and Human Retroviruses
language:en
Short-container-title:AIDS Research and Human Retroviruses

Author:

Ciccullo Arturo¹²,Baldin Gianmaria¹³,Borghi Vanni⁴,Sterrantino Gaetana⁵,Madeddu Giordano⁶,Latini Alessandra⁷,d'Ettorre Gabriella⁸,Lanari Alessandro⁹¹⁰,Mazzitelli Maria¹¹,Colafigli Manuela⁷,Capetti Amedeo Ferdinando¹²,Oreni Letizia¹³,Lagi Filippo⁵,Rusconi Stefano¹³,Di Giambenedetto Simona¹²

Affiliation:

1. Section of Infectious Diseases, Department of Safety and Bioethics, Catholic University of the Sacred Heart, Rome, Italy.

2. Infectious Diseases Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.

3. Mater Olbia Hospital, Olbia, Italy.

4. Department of Infectious Diseases, Azienda Ospedaliero-Universitaria Policlinico of Modena, Modena, Italy.

5. Division of Tropical and Infectious Diseases, ‘Careggi’ Hospital, Florence, Italy.

6. Department of Clinical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy.

7. Infectious Dermatology and Allergology Unit, IFO S. Gallicano Institute (IRCCS), Rome, Italy.

8. Department of Public Health and Infectious Diseases, Azienda Policlinico Umberto I, Rome, Italy.

9. Infectious Diseases Unit, AOU Senese, Siena, Italy.

10. Department of Medical Biotechnologies, University of Siena, Siena, Italy.

11. Department of Medical and Surgical Sciences, Unit of Infectious and Tropical Diseases, Magna Graecia University, Catanzaro, Italy.

12. Division of Infectious Diseases, Department of Infectious Diseases, Luigi Sacco University Hospital, Milan, Italy.

13. Infectious Diseases Unit, DIBIC Luigi Sacco, University of Milan, Milan, Italy.

Publisher

Mary Ann Liebert Inc

Subject

Infectious Diseases,Virology,Immunology

Link

https://www.liebertpub.com/doi/pdf/10.1089/aid.2020.0078

Reference20 articles.

1. HIV integrase inhibitors: a new era in the treatment of HIV

2. Brief Report

3. Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observ

4. Dolutegravir – a review of the pharmacology, efficacy, and safety in the treatment of HIV

5. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of switching to injectables cabotegravir and rilpivirine on sleep disturbances in a cohort of people living with HIV;HIV RES CLIN PRACT;2024

2. Achievement of Primary Prevention Cardiometabolic Targets in Women with HIV: An Urgent Call to Action to Pursue Cardiovascular Health;Viruses;2024-04-09

3. Characterization and outcomes of difficult-to-treat patients starting modern first-line ART regimens: Data from the ICONA cohort;International Journal of Antimicrobial Agents;2024-01

4. Changing Prevalence of AIDS and Non-AIDS-Defining Cancers in an Incident Cohort of People Living with HIV over 28 Years;Cancers;2023-12-22

5. Dolutegravir-induced growth and lifespan effects in Caenorhabditis elegans;BMC Pharmacology and Toxicology;2023-12-07